Vanda Pharmaceuticals has received an unsolicited, non-binding indication of interest from Cycle Group to acquire the company for $8.00 per share in cash. The Vanda Board of Directors will review and evaluate the indication of interest to determine the course of action that the Board believes is in the best interests of Vanda and its shareholders. There is no action for shareholders to take at this time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
- Vanda Pharma completes transfer of FDA Marketing Authorization for Ponvory
- Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders
- Vanda reports results from second Phase III study of tradipitant
- Biotech Alert: Searches spiking for these stocks today